A survey assessing the impact of COVID‐19 and elexacaftor/tezacaftor/ifavacaftor on both physical and mental health in adults with cystic fibrosis
暂无分享,去创建一个
C. Sakon | E. Tillman | H. Vogt | C. Brown
[1] E. Acosta,et al. Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis , 2022, Pediatric pulmonology.
[2] S. N,et al. Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[3] D. Waltz,et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. , 2021, The New England journal of medicine.
[4] W. Tindell,et al. Trikafta and Psychopathology in Cystic Fibrosis: A Case Report. , 2020, Psychosomatics.
[5] L. Lands,et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.
[6] F. van Goor,et al. VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles , 2018, The New England journal of medicine.